Related Experiment Video
Updated: Aug 6, 2026

Investigating Migraine-Like Behavior Using Light Aversion in Mice
Published on: August 11, 2021
[Pituitary adenylate-cyclase activating polypeptide (PACAP)-targeting treatment as a potential migraine prophylactic
János Tajti1, Anett Csáti1, Tamás Körtési2,3
1Szegedi Tudományegyetem, Szent-Györgyi Albert Orvostudományi Kar, Neurológiai Klinika, Szeged.
Background And Purpose:
In migraine prophylaxis, specific therapeutic options are provided by monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) and its receptor, CGRP receptor antagonists (gepants), and 5-hydroxytryptamine 1F receptor agonist ditans. mAbs acting on the pituitary adenylate cyclase-activating polypeptide (PACAP) or its receptor (PAC1) represent a new therapeutic target.
Methods:
A literature review based on a PubMed search.
Results:
Results from a Phase 2a randomized clinical trial using a human mAb against the PAC1 receptor (subcutaneous AMG 301) showed no difference between placebo and the active drug in reducing the number of monthly migraine days (MMD). The HOPE study (Phase 2) targeted PACAP as a ligand used low (100 mg) and high (750 mg) doses of an intravenous humanized mAb, Lu AG09222, in patients with episodic and chronic migraine. After 4 weeks of treatment, the reduction in MMDs from baseline was -6.2 days in the high-dose active group, compared to -4.2 days in the placebo group. A recently published Phase 2 clinical trial investigating a human mAb targeting PACAP (a single 1500 mg intravenous dose of LY3451838) showed no difference in the reduction of MMDs in patients with episodic and chronic migraine. The results of the ongoing PROCEED study, which evaluates the efficacy of four different doses of Lu AG09222 in migraine prevention, are expected to be published soon.
Conclusion:
Based on the findings from early-phase observations with mAbs against PACAP and its receptor, further high-phase clinical studies are required.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Angle Closure Glaucoma: Treatment
GPCRs Regulate Adenylyl Cylase Activity
Two...

